Intellia Therapeutics Inc. Share Price Today: Live Updates & Key Insights

Intellia Therapeutics Inc. share price today is $13, up -2.36%. The stock opened at $13.05 against the previous close of $13.15, with an intraday high of $13.57 and low of $12.81.

Intellia Therapeutics Inc. Share Price Chart

Intellia Therapeutics Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Intellia Therapeutics Inc. Share Price Performance

$13 -0.0236(-2.36%) NTLA at 23 Mar 2026 02:31 PM Biotechnology
Lowest Today 12.81
Highest Today 13.57
Today’s Open 13.05
Prev. Close 13.15
52 Week High 28.25
52 Week Low 5.90
Day’s Range: Low 12.81 High 13.57
52-Week Range: Low 5.90 High 28.25
1 day return -
1 Week return -3.99
1 month return -2.35
3 month return +32.57
6 month return -25.53
1 year return +38.27
3 year return -65.43
5 year return -81.21
10 year return -

Intellia Therapeutics Inc. Institutional Holdings

ARK Investment Management LLC 12.03

Vanguard Group Inc 11.01

BlackRock Inc 7.85

ARK Innovation ETF 7.64

ARK Disruptive Innovation Full Composite 7.60

Morgan Stanley - Brokerage Accounts 5.10

D. E. Shaw & Co LP 4.51

State Street Corp 4.21

The Goldman Sachs Group Inc 3.62

Regeneron Pharmaceuticals Inc 3.13

Vanguard Total Stock Mkt Idx Inv 3.08

State Street® SPDR® S&P® Biotech ETF 3.06

ARK Genomic Revolution 2.54

ARK Genomic Revolution ETF 2.52

Two Sigma Investments LLC 2.28

Geode Capital Management, LLC 2.28

Vanguard Small Cap Index 2.22

iShares Russell 2000 ETF 2.11

Sumitomo Mitsui Trust Group Inc 1.99

Two Sigma Advisers, LLC 1.99

Amova Asset Management Americas, Inc 1.86

Dimensional Fund Advisors, Inc. 1.64

FMR Inc 1.49

VOLORIDGE INVESTMENT MANAGEMENT, LLC 1.47

Renaissance Technologies Corp 1.42

Vanguard Strategic Equity Inv 1.33

Vanguard Small Cap Growth Index Inv 1.24

Amova ARK Disruptive Innovation A USD 1.18

Fidelity Select Biotechnology 1.13

Vanguard Institutional Extnd Mkt Idx Tr 1.06

Armistice Capital, LLC 0.98

UBS Group AG 0.94

Jupiter Asset Management Limited 0.88

Fidelity Small Cap Index 0.85

Jupiter Merian Glb Eq AbsRet I USD Acc 0.79

iShares Russell 2000 Value ETF 0.75

iShares Biotechnology ETF 0.69

Contrarius Global Equity Institutional 0.56

Fidelity Extended Market Index 0.52

State St Russell Sm/Mid Cp® Indx SL Cl I 0.51

Intellia Therapeutics Inc. Market Status

Strong Buy: 18

Buy: 4

Hold: 6

Sell: 1

Strong Sell: 0

Intellia Therapeutics Inc. Fundamentals

Market Cap 1516.83 M

PB Ratio 2.261

PE Ratio 0.0

Enterprise Value 1161.46 M

Total Assets 842.13 M

Volume 5219356

Intellia Therapeutics Inc. Company Financials

Annual Revenue FY23:51765000 51.8M, FY22:52121000 52.1M, FY21:33053000 33.1M, FY20:57994000 58.0M, FY19:43103000 43.1M

Annual Profit FY23:null 0.0M, FY22:52121000 52.1M, FY21:33053000 33.1M, FY20:57994000 58.0M, FY19:43103000 43.1M

Annual Net worth FY23:-462438000 -462.4M, FY22:-490208000 -490.2M, FY21:-259718000 -259.7M, FY20:-125568000 -125.6M, FY19:-92698000 -92.7M

Quarterly Revenue Q3/2025:13782000 13.8M, Q2/2025:14245000 14.2M, Q1/2025:16627000 16.6M, Q3/2024:9111000 9.1M, Q2/2024:6957000 7.0M

Quarterly Profit Q3/2025:-65167000 -65.2M, Q2/2025:14245000 14.2M, Q1/2025:16627000 16.6M, Q3/2024:9111000 9.1M, Q2/2024:4358000 4.4M

Quarterly Net worth Q3/2025:-101324000 -101.3M, Q2/2025:-101255000 -101.3M, Q1/2025:-114329000 -114.3M, Q3/2024:-135712000 -135.7M, Q2/2024:-146975000 -147.0M

About Intellia Therapeutics Inc. & investment objective

Company Information Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 377

Industry Biotechnology

CEO Dr. John M. Leonard M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Intellia Therapeutics Inc. FAQs

What is the share price of Intellia Therapeutics Inc. today?

The current share price of Intellia Therapeutics Inc. is $13.

Can I buy Intellia Therapeutics Inc. shares in India?

Yes, Indian investors can buy Intellia Therapeutics Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Intellia Therapeutics Inc. shares in India?

You can easily invest in Intellia Therapeutics Inc. shares from India by:

Can I buy fractional shares of Intellia Therapeutics Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Intellia Therapeutics Inc.?

Intellia Therapeutics Inc. has a market cap of $1516.83 M.

In which sector does Intellia Therapeutics Inc. belong?

Intellia Therapeutics Inc. operates in the Biotechnology sector.

What documents are required to invest in Intellia Therapeutics Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Intellia Therapeutics Inc.?

The PE ratio of Intellia Therapeutics Inc. is N/A and the PB ratio is 2.26.